Cellestis has not disclosed its profit margin, however we believe it is in the region of 60%-70%, in a market which could potentially see annual sales of upwards of $1 billion or more.
Global Monopoly
QFTG has patent protection until 2017 and possibly 2021. Cellestis is in the unique position of having a product which will be in high demand and for which there is no competitor. QFTG is a cheap product to buy at $US17.00, which supports volume selling, while also providing scope for future price increases.
“Blue Sky” Potential
QFTG operates off a new revolutionary “Quantiferon” platform technology for measuring Cell Mediated Immune (CMI) response. Current methods of measuring the CMI response are cumbersome, messy, expensive and take up to a week. Quantiferon is an easy, simple, inexpensive blood test which produces a result within hours. The first commercial application of Quantiferon is for TB, but the technology has possible applications in autoimmune diseases, cancer and many other infectious diseases. Cellestis is in the process of commercialising new diagnostics for Cytomegalovirus and Leishmaniasis.
Cellestis is a unique global investment and its potential value, based on QFTG alone, is many times its current stock price of around $3.00.
“We are selling a significant medical change. Our company has big goals. To capture most or all of the more than 30 million TB infection tests done each year in the developed world.
We have very significant achievements. We have obtained critical IP, market approvals and guidelines in all major markets, established worldwide brand recognition, and made inroads in all key world markets.”
- Cellestis Presentation 02/10/2006
CST Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
